CAN-AIM to PREVENT: CANadian Study, Assessing Inflammatory Markers to PRedict EVents in Nephrology sTudy
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 2,530
- Primary Endpoint
- Renal function at study censure
Study Overview
Brief Summary
Longitudinal cohort of patients with chronic kidney disease followed in 3 kidney centers in Ontario. The goal is to determine whether and how rates of renal disease progression are affected by inflammatory markers, FGF23 levels, and genetic polymorphisms
Detailed Description
This longitudinal cohort study will follow 2500 prevalent Chronic Kidney Disease (CKD)patients under the care of a nephrologist at 3 Southern Ontario Nephrology centres and all affiliated satellite centres with an estimated Glomerular Filtration Rate (eGFR) less than 60 ml/min to determine the rate of their renal disease progression over a 36 months. All CKD patients older than 18 years of age may be included in this study. This study will analyze, with 6 month serial measurements, conventional biochemical, hormonal and metabolic parameters in addition to the demographics, clinical status, medications and blood and urine samples of these patients. This study will assess the influence of inflammation on FGF23 and genetic polymorphisms that may reflect the processes involved with disease progression.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients referred to a nephrologist for evaluation of CKD or those currently seen by a nephrologist, with eGFR less than 60 ml/min
- •Patients that are erythropoietin treatment naive
- •Transplant patients with failing grafts requiring nephrologists follow-up
- •Patients currently not receiving RRT consenting to be in the study
- •Adults 18 years of age and older
Exclusion Criteria
- •Functioning Organ transplant
- •Life expectancy less than 12 months
- •Patients currently receiving RRT or who will likely initiate RRT within 6 months
- •Patients unable or contraindicated to receive EPREX® as erythropoietin replacement therapy for the correction of anemia related to CKD
Outcomes
Primary Outcomes
Renal function at study censure
Time Frame: 3 years
Estimated glomerular filtration rate after 3 years of follow-up in the study
Secondary Outcomes
- Dialysis-dependent renal failure(3 years)